The Society of Thoracic Surgeons Coronary Artery Bypass Graft Composite Measure: 2021 Methodology Update.


Journal

The Annals of thoracic surgery
ISSN: 1552-6259
Titre abrégé: Ann Thorac Surg
Pays: Netherlands
ID NLM: 15030100R

Informations de publication

Date de publication:
06 2022
Historique:
received: 16 04 2021
revised: 25 05 2021
accepted: 01 06 2021
pubmed: 20 7 2021
medline: 26 5 2022
entrez: 19 7 2021
Statut: ppublish

Résumé

The Society of Thoracic Surgeons (STS) original coronary artery bypass graft surgery (CABG) composite measure uses a 1-year analytic cohort and 98% credible intervals (CrI) to classify better than expected (3-star) performance or worse than expected (1-star) performance. As CABG volumes per STS participant (eg, hospital or practice group) have decreased, it has become more challenging to classify performance categories using this approach, especially for lower volume programs, and alternative approaches have been explored. Among 990 STS Adult Cardiac Surgery Database participants, performance classifications for the CABG composite were studied using various analytic cohorts: 1 year (current approach, 2017); 3 years (2015 to 2017); last 450 cases within 3 years; and most recent year (2017) plus additional cases to 450 total. We also compared 98% CrI with 95% CrI (used in other STS composite measures). Using 3 years of data and 95% CrIs, 113 of 990 participants (11.4%) were classified 1-star and 198 (20%) 3-star. Compared with 1-year analytic cohorts and 98% CrI, the absolute and relative increases in the proportion of 3-star participants were 14 percentage points and 233% (n = 198 [20%] vs n = 59 [6%]). Corresponding changes for 1-star participants were 6.5 percentage points and 133% (n = 113 [11.4%] vs n = 48 [4.9%]). These changes were particularly notable among lower volume (fewer than 199 CABG per year) participants. Measure reliability with the 3-year, 95% CrI modification is 0.78. Compared with current STS CABG composite methodology, a 3-year analytic cohort and 95% CrI increases the number and proportion of better or worse than expected outliers, especially among lower-volume Adult Cardiac Surgery Database participants. This revised methodology is also now consistent with other STS procedure composites.

Sections du résumé

BACKGROUND
The Society of Thoracic Surgeons (STS) original coronary artery bypass graft surgery (CABG) composite measure uses a 1-year analytic cohort and 98% credible intervals (CrI) to classify better than expected (3-star) performance or worse than expected (1-star) performance. As CABG volumes per STS participant (eg, hospital or practice group) have decreased, it has become more challenging to classify performance categories using this approach, especially for lower volume programs, and alternative approaches have been explored.
METHODS
Among 990 STS Adult Cardiac Surgery Database participants, performance classifications for the CABG composite were studied using various analytic cohorts: 1 year (current approach, 2017); 3 years (2015 to 2017); last 450 cases within 3 years; and most recent year (2017) plus additional cases to 450 total. We also compared 98% CrI with 95% CrI (used in other STS composite measures).
RESULTS
Using 3 years of data and 95% CrIs, 113 of 990 participants (11.4%) were classified 1-star and 198 (20%) 3-star. Compared with 1-year analytic cohorts and 98% CrI, the absolute and relative increases in the proportion of 3-star participants were 14 percentage points and 233% (n = 198 [20%] vs n = 59 [6%]). Corresponding changes for 1-star participants were 6.5 percentage points and 133% (n = 113 [11.4%] vs n = 48 [4.9%]). These changes were particularly notable among lower volume (fewer than 199 CABG per year) participants. Measure reliability with the 3-year, 95% CrI modification is 0.78.
CONCLUSIONS
Compared with current STS CABG composite methodology, a 3-year analytic cohort and 95% CrI increases the number and proportion of better or worse than expected outliers, especially among lower-volume Adult Cardiac Surgery Database participants. This revised methodology is also now consistent with other STS procedure composites.

Identifiants

pubmed: 34280375
pii: S0003-4975(21)01245-5
doi: 10.1016/j.athoracsur.2021.06.036
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1954-1961

Informations de copyright

Copyright © 2022 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.

Auteurs

David M Shahian (DM)

Division of Cardiac Surgery, Department of Surgery, and Center for Quality and Safety, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts. Electronic address: dshahian@partners.org.

Michael E Bowdish (ME)

Department of Surgery, Keck School of Medicine of USC, University of Southern California, Los Angeles, California; Department of Preventive Medicine, Keck School of Medicine of USC, University of Southern California, Los Angeles, California.

Jordan P Bloom (JP)

Division of Cardiac Surgery, Department of Surgery, Massachusetts General Hospital, Boston, Massachusetts.

Moritz C Wyler von Ballmoos (MC)

Houston Methodist DeBakey Heart and Vascular Center, Houston, Texas.

James R Edgerton (JR)

Division of Cardiothoracic Surgery, Department of Surgery, Washington University School of Medicine, Barnes-Jewish Hospital, St. Louis, Missouri; Baylor Research Institute, Dallas, Texas.

Mark S Antman (MS)

The Society of Thoracic Surgeons, Chicago, Illinois.

Paul A Kurlansky (PA)

College of Physicians and Surgeons, Columbia University, New York, New York.

Kevin W Lobdell (KW)

Atrium Health, Cardiovascular and Thoracic Surgery, Charlotte, North Carolina.

Joseph C Cleveland (JC)

Division of Cardiothoracic Surgery, Department of Surgery, University of Colorado, Aurora, Colorado.

Mario F L Gaudino (MFL)

Department of Cardiothoracic Surgery, Weill Cornell Medicine, New York, New York.

Gaetano Paone (G)

Division of Cardiothoracic Surgery, Emory University School of Medicine, Atlanta, Georgia.

Christina Vassileva (C)

Integrity Medical Consulting LLC, Shrewsbury, Massachusetts.

Vinod H Thourani (VH)

Department of Cardiovascular Surgery, Marcus Valve Center, Piedmont Heart Institute, Atlanta, Georgia.

Anthony P Furnary (AP)

Starr-Wood Cardiothoracic Group, Portland, Oregon.

Vinay Badhwar (V)

Department of Cardiovascular and Thoracic Surgery, West Virginia University, Morgantown, West Virginia.

Jeffrey P Jacobs (JP)

Division of Cardiovascular Surgery, Department of Surgery, University of Florida, Gainesville, Florida.

Sean M O'Brien (SM)

Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH